文献速递肝病

肝移植后原发性硬化性胆管炎复发:法国571例全国队列研究

Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation: A French National Cohort Study Including 571 Patients.
PubMed 文献 · Am J Gastroenterol · 2025-07-24

这项法国全国多中心回顾性研究纳入1985年3月至2019年3月因原发性硬化性胆管炎(PSC)接受肝移植的571例成人患者,评估复发PSC(rPSC)的发生率、特征及危险因素。中位随访7.4年,rPSC总体发生率为25.9%,5、15、25年累积风险分别为15.6%、37.9%、52.6%。独立危险因素包括合并炎症性肠病(IBD)、维持性糖皮质激素治疗及移植时年龄较轻;胆道吻合方式或熊去氧胆酸预防治疗对rPSC发生率无影响。

要点

  • 肝移植后PSC复发常见,25年累积风险达52.6%。
  • 合并IBD、维持激素治疗及移植时年龄较轻与rPSC独立相关。
  • 维持性糖皮质激素是唯一可干预因素,无肝外指征时可考虑停用。

核心结论

  • 肝移植后PSC复发频繁,长期随访累积风险高。
  • 维持性糖皮质激素是唯一可干预的rPSC相关因素,无特定肝外指征时可停用。

研究设计与样本

  • 法国全国多中心回顾性研究,纳入1985年3月至2019年3月因PSC接受肝移植的成人患者共571例(男性389例,68.1%),移植时中位年龄42.0岁(IQR 32.0-52.8),移植后中位随访7.4年(IQR 3.6-12.6)。

主要发现

  • rPSC总体发生率为25.9%,5、15、25年累积风险分别为15.6%、37.9%、52.6%,中位复发时间4.9年(IQR 2.3-8.9)。
  • 合并IBD与rPSC独立相关(HR 1.97,95%CI 1.24-3.14)。
  • 维持性糖皮质激素治疗与rPSC独立相关(HR 1.76,95%CI 1.17-2.66)。
  • 移植时年龄较轻与rPSC独立相关(每增加1岁HR 1.02,95%CI 1.01-1.03)。
  • 胆道吻合类型或熊去氧胆酸预防治疗对rPSC发生率无影响。

临床怎么用

  • 对肝移植后PSC患者应长期监测rPSC,尤其合并IBD、移植时年轻及接受维持激素治疗者。
  • 无特定肝外指征时,可考虑停用维持性糖皮质激素以降低rPSC风险。

局限性

  • 本研究为回顾性研究,原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Primary sclerosing cholangitis (PSC) may recur after liver transplantation (LT). We aimed to evaluate the incidence of recurrent PSC (rPSC), its characteristics, and risk factors, in a large cohort with long-term follow-up. METHODS: We conducted a nationwide multicenter retrospective study in France, including all adult patients transplanted for PSC from March 1985 to March 2019. Clinical, biological, and histological data were collected. Risk factors for rPSC were identified using a multivariate Cox-regression model. RESULTS: Five hundred seventy-one patients were included (389 males, 68.1%) with a median age at LT of 42.0 (interquartile range [IQR] 32.0-52.8). Median follow-up after LT was 7.4 years (IQR 3.6-12.6). Overall, rPSC occurred in 25.9% of patients; actuarial risk of developing rPSC at 5, 15, and 25 years was 15.6%, 37.9%, and 52.6%, respectively. The median time to rPSC was 4.9 years (IQR 2.3-8.9). The factors independently associated with rPSC were the presence of IBD (hazard ratio [HR] 1.97, 95% confidence interval [CI] 1.24-3.14), maintenance treatment with corticosteroids (HR 1.76, 95% CI 1.17-2.66), and younger age at LT (HR 1.02 per 1-year increase, 95% CI 1.01-1.03). Type of biliary anastomosis or preventive treatment with ursodeoxycholic acid had no impact on the incidence of rPSC. DISCUSSION: Our results from a large cohort with long-term follow-up strongly confirm that rPSC after LT is frequent. The only modifiable factor associated with rPSC was maintenance treatment with corticosteroids, which could therefore be discontinued in the absence of a specific extrahepatic indication.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Veyre F, De Martin E, Erard D, et al. Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation: A French National Cohort Study Including 571 Patients. Am J Gastroenterol. 2025. PMID: 40736679. doi:10.14309/ajg.0000000000003659

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。